Silence Therapeutics insider sells 1.54M ADSs

Silence Therapeutics plc 10% owner Richard Ian Griffiths reported a series of open-market sales of American Depositary Shares (ADSs) associated with his holdings.

Rhea-AI Filing Summary

Silence Therapeutics plc 10% owner Richard Ian Griffiths reported a series of open-market sales of American Depositary Shares (ADSs) associated with his holdings. Across six transactions between June 29 and July 6, 2026, entities linked to him sold an aggregate of 1,544,374 ADSs.

The ADSs were sold indirectly through interests, including Cream Capital Limited, with Griffiths disclaiming beneficial ownership beyond his proportionate pecuniary interest. Following these transactions, he continued to report 10,281,486 ADSs held indirectly. Each ADS is immediately convertible into three ordinary shares for no consideration and has no expiration date.

Insider Trade Summary

Net Seller: 1,544,374 shares

Net Sell 6 txns

Insider Griffiths Richard Ian

Role 10% Owner

Sold 1,544,374 shs ($0.00)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares	865,112	$0.00	$0.00
Sale	American Depositary Shares	50,082	$0.00	$0.00
Sale	American Depositary Shares	79,180	$0.00	$0.00
Sale	American Depositary Shares	50,000	$0.00	$0.00
Sale	American Depositary Shares	169,928	$0.00	$0.00
Sale	American Depositary Shares	330,072	$0.00	$0.00

Holdings After Transaction: American Depositary Shares — 66,693,092 contracts (Indirect, See footnote)

Footnotes (2)

1. F1. Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.
2. F2. The securities were sold by Cream Capital Limited ("CCL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Key Figures

ADSs sold: 1,544,374 ADSs ADSs held after transactions: 10,281,486 ADSs Number of sale transactions: 6 transactions +1 more

4 metrics

ADSs sold 1,544,374 ADSs Aggregate open-market sales June 29–July 6, 2026

ADSs held after transactions 10,281,486 ADSs Indirect holdings reported following July 6, 2026 sales

Number of sale transactions 6 transactions Open-market or private sales in the Form 4

ADS to ordinary share ratio 1 ADS = 3 ordinary shares Each ADS immediately convertible for no consideration

Key Terms

American Depositary Shares, open-market sale, indirect ownership, beneficial ownership, +1 more

5 terms

American Depositary Shares financial

"The filing reports sales of American Depositary Shares linked to Griffiths."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

open-market sale financial

"Each transaction is characterized as an open-market sale of ADSs."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"The ADS holdings are reported as indirect ownership through related entities."

beneficial ownership financial

"Griffiths disclaims beneficial ownership beyond his pecuniary interest."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

ordinary shares financial

"Each ADS is convertible into three underlying ordinary shares."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Silence Therapeutics (SLN) report for Richard Ian Griffiths?

Silence Therapeutics reported that 10% owner Richard Ian Griffiths had entities linked to him execute six open-market sales of American Depositary Shares, totaling 1,544,374 ADSs between June 29 and July 6, 2026, according to the Form 4 filing.

How many Silence Therapeutics (SLN) ADSs were sold in the latest Form 4?

The Form 4 shows aggregate open-market sales of 1,544,374 American Depositary Shares. These sales occurred over six transactions from June 29 through July 6, 2026, and involved indirect holdings associated with Richard Ian Griffiths, including Cream Capital Limited.

How many Silence Therapeutics (SLN) ADSs does Richard Ian Griffiths report after these sales?

After the reported transactions, Richard Ian Griffiths continues to report indirect ownership of 10,281,486 American Depositary Shares. This figure represents his remaining position following the series of open-market sales disclosed in the Form 4 filing.

Who actually sold the Silence Therapeutics (SLN) shares disclosed in the Form 4?

The filing states the securities were sold by Cream Capital Limited and by Richard Ian Griffiths personally. Griffiths is a director and controlling shareholder of Cream Capital Limited but disclaims beneficial ownership beyond his proportionate pecuniary interest in those securities.

How are Silence Therapeutics (SLN) American Depositary Shares structured in this filing?

Each American Depositary Share is immediately convertible into three ordinary shares for no consideration and has no expiration date. This means every ADS represents three underlying ordinary shares of Silence Therapeutics, according to the Form 4 footnote.

Were the Silence Therapeutics (SLN) insider transactions classified as open-market sales?

Yes. Each transaction in the Form 4 is coded with “S” and described as an open-market or private sale. The filing characterizes all six reportable trades as open-market sales of American Depositary Shares linked to Richard Ian Griffiths’ indirect holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 09:09 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Griffiths Richard Ian

(Last) (First) (Middle)

(Street)

ST HELIER Y9 JE2 3AS

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Silence Therapeutics plc [ SLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	$10.69	06/29/2026		S		330,072		(1)	(1)	Ordinary Shares	990,216	(1)	11,495,788	I	See footnote(2)
American Depositary Shares	$10.76	06/30/2026		S		169,928		(1)	(1)	Ordinary Shares	509,784	(1)	11,325,860	I	See footnote(2)
American Depositary Shares	$10.62	07/01/2026		S		79,180		(1)	(1)	Ordinary Shares	237,540	(1)	11,246,680	I	See footnote(2)
American Depositary Shares	$10.62	07/01/2026		S		50,000		(1)	(1)	Ordinary Shares	150,000	(1)	11,196,680	I	See footnote(2)
American Depositary Shares	$10.47	07/02/2026		S		50,082		(1)	(1)	Ordinary Shares	150,246	(1)	11,146,598	I	See footnote(2)
American Depositary Shares	$10.53	07/06/2026		S		865,112		(1)	(1)	Ordinary Shares	2,595,336	(1)	10,281,486	I	See footnote(2)

Explanation of Responses:

1. Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.

2. The securities were sold by Cream Capital Limited ("CCL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

	/s/ Richard Ian Griffiths	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)